Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-18-008 from the NIH Guide for Grants and Contracts. This FOA invites applications to fund continuation of the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), a screening and clinical activities coordination unit. The main objective of the HUB is to develop creative approaches to screening, recruitment, and trial implementation, and to increase the operational efficiency and flexibility of the TrialNet network. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - January 10, 2019 Category: Research Source Type: funding
Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed)
This FOA invites applications to fund continuation of the Type 1 Diabetes TrialNet Clinical Network Hub (HUB), a screening and clinical activities coordination unit. The main objective of the HUB is to develop creative approaches to screening, recruitment, and trial implementation, and to increase the operational efficiency and flexibility of the TrialNet network.RFA-DK-18-008 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - January 10, 2019 Category: Endocrinology Source Type: funding
Limited Competition for the Continuation of the Coordinating Center for Type 1 Diabetes TrialNet (U01 Clinical Trial Required)
This Funding Opportunity Announcement (FOA) invites an application from the Program Director/Principal Investigator of the Coordinating Center (TNCC) that is currently supporting the research being performed by the Type 1 Diabetes TrialNet network. This FOA will support the TNCC in its oversight of the screening of relatives of individuals with type 1 diabetes (T1D) for monitoring and possible inclusion in intervention studies aimed at preservation of insulin-producing cells. The FOA will also support the TNCC in its design, conduct and continuation of intervention studies in individuals at early pre-clinical stages of T1D...
Source: NIDDK Funding Opportunities - January 10, 2019 Category: Endocrinology Source Type: funding
Notice of Special Interest in Understanding Factors in Infancy and Early Childhood (Birth to 24 months) That Influence Obesity Development
The purpose of this Notice is to inform potential applicants to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute on Minority Health and Health Disparities (NIMHD), and Office of Behavioral and Social Sciences Research (OBSSR) of an area of special interest in understanding factors in infancy and early childhood (birth to 24 months) that influence the development of obesity.Voula Osganian, M.D., Sc.D., M.P.H. | NOT-DK-19-007 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - January 7, 2019 Category: Endocrinology Source Type: funding
Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
Funding Opportunity PAS-19-105 from the NIH Guide for Grants and Contracts. The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonma...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 17, 2018 Category: Research Source Type: funding
Human Islet Research Network - Consortium on Modeling Autoimmune Interactions (HIRN-CMAI) (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-18-013 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites new and renewal applications to participate in the Consortium on Modeling Autoimmune Interactions (CMAI). CMAI is a component of the Human Islet Research Network (HIRN) that is focused on developing robust systems to measure and model the biology of human type 1 diabetes. Projects will explore and validate research models designed to advance pre-clinical scientific discovery, mechanistic dissection of disease processes, and testing of potential interventions for T1D. (Source: NIH Funding Opp...
Source: NIH Funding Opportunities (Notices, PA, RFA) - December 17, 2018 Category: Research Source Type: funding
Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the le...
Source: NIDDK Funding Opportunities - December 17, 2018 Category: Endocrinology Source Type: funding
Stimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood Institute (NHLBI). Investigator-initiated research project grant applications (R01s) in specific areas of basic and early translational hematology research are invited to this program that supports growth in the nonmalignant hematology research domain. Specific emerging topics that are at the l?...
Source: NIDDK Funding Opportunities - December 17, 2018 Category: Endocrinology Source Type: funding
Human Islet Research Network - Consortium on Modeling Autoimmune Interactions (HIRN-CMAI) (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites new and renewal applications to participate in the Consortium on Modeling Autoimmune Interactions (CMAI). CMAI is a component of the Human Islet Research Network (HIRN) that is focused on developing robust systems to measure and model the biology of human type 1 diabetes. Projects will explore and validate research models designed to advance pre-clinical scientific discovery, mechanistic dissection of disease processes, and testing of potential interventions for T1D.RFA-DK-18-013 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - December 17, 2018 Category: Endocrinology Source Type: funding
Support for Small Business Innovation Research to Develop New Open and Closed-Loop Automated Technologies for Better Type 1 Diabetes Therapy and Monitoring (SBIR) (R43/R44 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-18-022 from the NIH Guide for Grants and Contracts. The goal of this Funding Opportunity Announcement (FOA) is to stimulate bioengineers, physiologists, bio-behavioral researchers, and designers in academic centers and small businesses to develop new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies including open and closed loop hormone replacement systems. (Source: NIH Funding Opportunities (Notices, PA, RFA))
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 26, 2018 Category: Research Source Type: funding
Support for Small Business Innovation Research to Develop New Open and Closed-Loop Automated Technologies for Better Type 1 Diabetes Therapy and Monitoring (SBIR) (R43/R44 Clinical Trial Not Allowed)
The goal of this Funding Opportunity Announcement (FOA) is to stimulate bioengineers, physiologists, bio-behavioral researchers, and designers in academic centers and small businesses to develop new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies including open and closed loop hormone replacement systems.Guillermo Arreaza-Rubin, M.D. | RFA-DK-18-022 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - November 26, 2018 Category: Endocrinology Source Type: funding
Data Coordinating Center for the Diabetic Foot Consortium (U24 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-18-010 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for a Data Coordinating Center (DCC) that will support the Diabetic Foot Consortium (DFC) for clinical research on diabetic foot ulcers. The first studies will validate biomarkers that predict healing or response to therapy and assess infection or recurrence risk. Future research may involve clinical trials and studies on the pathophysiology of diabetic foot ulcers. Given the clinical complexity of diabetic wound healing, the applicant must have experience serving as the DCC on ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - November 8, 2018 Category: Research Source Type: funding
Data Coordinating Center for the Diabetic Foot Consortium (U24 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites applications for a Data Coordinating Center (DCC) that will support the Diabetic Foot Consortium (DFC) for clinical research on diabetic foot ulcers. The first studies will validate biomarkers that predict healing or response to therapy and assess infection or recurrence risk. Future research may involve clinical trials and studies on the pathophysiology of diabetic foot ulcers. Given the clinical complexity of diabetic wound healing, the applicant must have experience serving as the DCC on clinical studies of diabetic foot ulcers. The DCC will provide overall project coo...
Source: NIDDK Funding Opportunities - November 8, 2018 Category: Endocrinology Source Type: funding
Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) solicits applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through the controlled manipulation of beta cell replication, islet cell plasticity, and the reprogramming of pancreatic non-beta cells into beta-like cells, or through shielding the residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN). Olivier C Blondel, PHD | RFA-DK-18-014 (Source: NIDDK Funding Opportunities)
Source: NIDDK Funding Opportunities - November 2, 2018 Category: Endocrinology Source Type: funding
Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-18-014 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) solicits applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through the controlled manipulation of beta cell replication, islet cell plasticity, and the reprogramming of pancreatic non-beta cells into beta-like cells, or through shielding the residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Resea...
Source: NIH Funding Opportunities (Notices, PA, RFA) - October 31, 2018 Category: Research Source Type: funding
